MX2010002116A - Un modulador de nrg1 para el tratamiento de trastornos respiratorios. - Google Patents

Un modulador de nrg1 para el tratamiento de trastornos respiratorios.

Info

Publication number
MX2010002116A
MX2010002116A MX2010002116A MX2010002116A MX2010002116A MX 2010002116 A MX2010002116 A MX 2010002116A MX 2010002116 A MX2010002116 A MX 2010002116A MX 2010002116 A MX2010002116 A MX 2010002116A MX 2010002116 A MX2010002116 A MX 2010002116A
Authority
MX
Mexico
Prior art keywords
nrg1
treatment
modulators
relates
modulator
Prior art date
Application number
MX2010002116A
Other languages
English (en)
Inventor
Carol Elizabeth Jones
Alan Jackson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010002116A publication Critical patent/MX2010002116A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a moduladores de la familia de Neurregulina (NRO), en particular NRG1, y más particularmente la NRGß, y de una manera muy particular la NRG1ß1. La presente invención también se refiere al uso de estos moduladores para inhibir la hiperplasia de células caliciformes, y por consiguiente, también se refiere al uso de estos moduladores en el tratamiento o en la prevención de enfermedades y trastornos humanos que presenten una producción patológica de moco, tal como enfermedad pulmonar obstructiva crónica (COPD), fibrosis quística (CF), bronquitis crónica, y asma.
MX2010002116A 2007-08-24 2008-08-22 Un modulador de nrg1 para el tratamiento de trastornos respiratorios. MX2010002116A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114972 2007-08-24
PCT/EP2008/061009 WO2009027332A1 (en) 2007-08-24 2008-08-22 A modulator of nrg1 for treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
MX2010002116A true MX2010002116A (es) 2010-03-26

Family

ID=38668734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002116A MX2010002116A (es) 2007-08-24 2008-08-22 Un modulador de nrg1 para el tratamiento de trastornos respiratorios.

Country Status (11)

Country Link
US (2) US20110070247A1 (es)
EP (1) EP2192955A1 (es)
JP (1) JP2010536830A (es)
KR (1) KR20100046215A (es)
CN (1) CN101784302A (es)
AU (1) AU2008292262B2 (es)
BR (1) BRPI0816142A2 (es)
CA (1) CA2697378A1 (es)
EA (1) EA201000337A1 (es)
MX (1) MX2010002116A (es)
WO (1) WO2009027332A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2021142245A1 (en) * 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US20050208527A1 (en) * 2000-02-28 2005-09-22 Decode Genetics Ehf. Human schizophrenia gene
CA2400595A1 (en) * 2000-02-28 2001-09-07 Decode Genetics Ehf Human schizophrenia gene
JPWO2006062135A1 (ja) * 2004-12-07 2008-06-12 独立行政法人理化学研究所 精神疾患の診断薬
CN101495503A (zh) * 2005-03-07 2009-07-29 塔盖替德分子诊断有限公司 酪氨酸激酶抑制剂组合物及其制造方法和在疾病治疗中的应用
JP2008545753A (ja) * 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof

Also Published As

Publication number Publication date
AU2008292262B2 (en) 2012-05-31
CN101784302A (zh) 2010-07-21
US20110070247A1 (en) 2011-03-24
US8658165B2 (en) 2014-02-25
CA2697378A1 (en) 2009-03-05
KR20100046215A (ko) 2010-05-06
EP2192955A1 (en) 2010-06-09
AU2008292262A1 (en) 2009-03-05
JP2010536830A (ja) 2010-12-02
BRPI0816142A2 (pt) 2015-02-18
US20130034567A1 (en) 2013-02-07
EA201000337A1 (ru) 2010-10-29
WO2009027332A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
JO2576B1 (en) Antibodies
MX2009013990A (es) Metodos para tratar enfermedades y trastornos mediados por serotonina.
WO2007042309A3 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IL212958B (en) Placental stem cells for the treatment of diseases, syndromes or conditions of the lungs
IN2012DN00624A (es)
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2008137633A3 (en) Methods of modulating cellular homeostatic pathways and cellular survival
HK1146485A1 (es)
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
MX2009004108A (es) Compuestos de tetrahidropirrolopiracina sustituidos teniendo afinidad al canal kcnq2/3 k+ y su uso en farmacos.
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
EP3712264A8 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
MY160560A (en) Compositions and methods for treatment of kidney disorders
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2008096203A3 (en) Food extracts containing n-methylnicotinamide for treatment of lipoprotein abnormalities and skin diseases and disorders
WO2011075606A3 (en) Hyperglycosylated polypeptide variants and methods of use

Legal Events

Date Code Title Description
FG Grant or registration